Genotypic resistance in HIV-1 - Infected patients with persistent low-level viremia;Resistencias genotípicas en pacientes con VIH-1 y grados de viremia persistentemente bajos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue 2, 2009, Pages 75-80

  Parra Ruiz, Jorge ^a   Álvarez, Marta ^a   Chueca, Natalia ^a   Peña, Alejandro ^a   Pasquau, Juan ^b   López Ruz, Miguel Ángel ^b   Maroto, María Del Carmen ^a   Hernández Quero, José ^a   García, Federico ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Genotypic resistance; HAART; Persistent low level viremia

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; RNA EXTRACTION; SENSITIVITY ANALYSIS; VIREMIA; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; RNA, VIRAL; SELECTION (GENETICS); SEQUENCE ANALYSIS, RNA; VIRAL LOAD; VIREMIA;

EID: 61649089222     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2008.02.007     Document Type: Article

References (23)

1. V. DeGruttola, L. Dix, R. D'Aquila, D. Holder, A. Phillips, and M. Ait-Khaled The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan Antivir Ther 5 2000 41 48
2. P.R. Harrigan, and H. Côté Clinical utility of testing human immunodeficiency virus for drug resistance Clin Infect Dis 30 Suppl 2 2000 S117 S122
3. A. Cingolani, A. Antinori, M.G. Rizzo, R. Murri, A. Ammassari, and F. Baldini Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) AIDS 16 2002 369 379
4. A.M. Vandamme, F. Houyez, D. Banhegyi, B. Clotet, G. De Schrijver, and K.A. De Smet Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up Antivir Ther 6 2001 21 39
5. Panel de expertos de GESIDA. Plan Nacional sobre el Sida. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana [citado Ene 2008]. Disponible en: http://www.gesida.seimc.org.
6. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents [citado 25 Ene 2006]. Disponible en: http://www.aidsinfo.nih.gov.
7. N. Mackie, S. Dustan, M.O. McClure, J.N. Weber, and J.R. Clarke Detection on HIV-1 antiretroviral resistance from patients with persistently low but detectable viremia J Virol Methods 119 2004 73 78
8. R.E. Nettles, T.L. Kieffer, R.P. Simmons, J. Cofrancesco Jr., R.D. Moore, and J.E. Gallant Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy Clin Infect Dis 39 2004 1030 1037
9. H.B. Gale, V.L. Kan, and R.C. Shinol Performance of the TruGene Human Immunodeficiency Virus Type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter Clin Vaccine Immunol 13 2006 235 238
10. L. Waters, S. Mandalia, and D. Asboe Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml AIDS 20 2006 778 779
11. D.V. Havlir, R. Bassett, D. Levitan, P. Gilbert, P. Tebas, and A.C. Collier Prevalence and predictive value of intermittent viremia with combination hiv therapy JAMA 286 2001 171 179
12. S. Sungkanuparph, R.K. Groger, E.T. Overton, V.J. Fraser, and W.G. Powderly Persistent low-level viraemia and virological failure in HIV-1 infected patients treated with Highly Active Antiretroviral Therapy HIV Med 7 2006 437 441
13. N.H. Tobin, G.H. Learn, S.E. Holte, Y. Wang, A.J. Melvin, and J.L. McKernan Evidence that low-level viremias during effective Highly Active Antiretroviral Therapy result from two processes: expression of archival virus and replication of virus J Virol 79 2005 9625 9634
14. Lloyd RM, Schuurman R, Stang HL, De Groot T, Hough LM, Burns DA, et al. Accuracy and reproductibility of ultra low-copy HIV viral genotyping. Qiagen news [revista electrónica]. 2000 [citado 17 Oct 2006]. Disponible en: http://www.qiagen.com.
15. H.F. Gunthard, J.K. Wong, C.C. Ignacio, J.C. Guatelli, N.L. Riggs, and D.V. Havlir Human immunodeficiency virus replicacion and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy J Virol 72 1998 2422 2428
16. M. Hermankova, S.C. Ray, C. Ruff, M. Powell-Davis, R. Ingersoll, and R.T. D'Aquila HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy JAMA 286 2001 196 207
17. K. Steegen, E. Demecheleer, N. De Cabooter, D. Nges, M. Temmerman, and P. Ndumbe A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance J Virol Methods 133 2006 137 145
18. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, et al. Evolution of drug resistance in HIV infected patients remaining on a virologically failing HAART regimen. En: Program and abstract of the 10th European AIDS Conference (EACS), 2005; Dublin, Ireland. Abstract PE17.4/2.
19. H. Hatano, P. Hunt, J. Weidler, E. Coakley, R. Hoh, and T. Liegler Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen CID 43 2006 1329 1336
20. S. Aleman, K. Söderbärg, U. Visco-Comandini, G. Sitbon, and A. Sönnerborg Drug resistance at low viremia in HIV-1 infected patients with antiretroviral combination therapy AIDS 16 2002 1039 1044
21. S. Napravnik, D. Edwards, P. Steward, B. Stalzer, E. Matteson, and J.J. Eron HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia J Acquir Immune Defic Syndr 40 2005 34 40
22. J.L. Blanco, M.A. Biglia, M. Arnedo, E. Martinez, J. Mallolas, and A. Milinkovic Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor AIDS 19 2005 829 831
23. Stone C, Holbrook J, Madsen H, Modha S, Craig C. Amplification and sequencing of HIV-1 from low viral load plasma samples and analysis and interpretation of sequences obtained. En: Program and abstract of the 4th European HIV Drug Resistance Workshop; March 29-31, 2006; Monte Carlo, Mónaco. Abstract 63.